PURPOSE: To evaluate the effectiveness of short-course radiotherapy (RT) with 30 Gy in 10 fractions for bleeding from advanced gastric cancer. METHODS: We reviewed the data for all patients with gastric cancer requiring blood transfusions due to gastric bleeding who were treated with RT at the Shizuoka Cancer Center Hospital between September 2002 and March 2007. Patients with curative-intent chemoradiotherapy or previous irradiation were excluded. RT was planned to deliver a total of 30 Gy at 3 Gy per fraction. We defined RT as effective if the patients did not require blood transfusions for 1 or more months after RT. RESULTS: Twenty-two out of 30 patients (73%) responded to RT, and rebleeding occurred in 11 (50%) of 22 patients responding to RT. The median actuarial time to rebleeding was 3.3 months. Twelve patients received concurrent chemoradiotherapy and had a significantly lower rebleeding rate than patients undergoing RT alone (P = 0.001). Among patients receiving CRT, 1 with grade 3 non-hematological toxicity and 5 with grade 3-4 hematological toxicity were observed. No Grade 3 or higher adverse events were observed in patients treated with RT alone. CONCLUSIONS: RT with 30 Gy in 10 fractions is an adequate treatment for bleeding from advanced gastric cancer, especially in patients with poor prognosis.
PURPOSE: To evaluate the effectiveness of short-course radiotherapy (RT) with 30 Gy in 10 fractions for bleeding from advanced gastric cancer. METHODS: We reviewed the data for all patients with gastric cancer requiring blood transfusions due to gastric bleeding who were treated with RT at the Shizuoka Cancer Center Hospital between September 2002 and March 2007. Patients with curative-intent chemoradiotherapy or previous irradiation were excluded. RT was planned to deliver a total of 30 Gy at 3 Gy per fraction. We defined RT as effective if the patients did not require blood transfusions for 1 or more months after RT. RESULTS: Twenty-two out of 30 patients (73%) responded to RT, and rebleeding occurred in 11 (50%) of 22 patients responding to RT. The median actuarial time to rebleeding was 3.3 months. Twelve patients received concurrent chemoradiotherapy and had a significantly lower rebleeding rate than patients undergoing RT alone (P = 0.001). Among patients receiving CRT, 1 with grade 3 non-hematological toxicity and 5 with grade 3-4 hematological toxicity were observed. No Grade 3 or higher adverse events were observed in patients treated with RT alone. CONCLUSIONS: RT with 30 Gy in 10 fractions is an adequate treatment for bleeding from advanced gastric cancer, especially in patients with poor prognosis.
Authors: Jeremy Tey; Michael F Back; Thomas P Shakespeare; Rahul K Mukherjee; Jiade J Lu; Khai Mun Lee; Lea Choung Wong; Cheng Nang Leong; Ming Zhu Journal: Int J Radiat Oncol Biol Phys Date: 2006-11-21 Impact factor: 7.038
Authors: Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson Journal: N Engl J Med Date: 2001-09-06 Impact factor: 91.245
Authors: Michelle M Kim; Vishal Rana; Nora A Janjan; Prajnan Das; Alexandria T Phan; Marc E Delclos; Paul F Mansfield; Jaffer A Ajani; Christopher H Crane; Sunil Krishnan Journal: Acta Oncol Date: 2008 Impact factor: 4.089
Authors: Kang Hun Koh; Kang Kim; Dae Hun Kwon; Bum Su Chung; Ji Youn Sohn; Dae Seon Ahn; Byung Jun Jeon; Seong Hun Kim; In Hee Kim; Sang Wook Kim; Seung Ok Lee; Soo Teik Lee; Dae Ghon Kim Journal: Gastric Cancer Date: 2012-10-05 Impact factor: 7.370
Authors: Edyta Wolny-Rokicka; Krzysztof Sutkowski; Aleksandra Grządziel; Żaneta Dorsz; Andrzej Tukiendorf; Jakub Lipiński; Jerzy Wydmański Journal: Mol Clin Oncol Date: 2016-04-07